论文部分内容阅读
目的:采用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)技术检测食管癌(EC)患者化疗敏感性血清蛋白质谱,指导临床EC患者化疗方案的选择。方法:收集2013年1月至2014年6月我院收治的EC术后复发并行含铂化疗的患者40例,按照化疗疗效分为敏感组和耐药组。将两组蛋白质双向凝胶电泳图谱用Image Master 2D platinum 5.0软件分析并匹配,筛选出两组差异斑点,并采用MALDI-TOF-MS技术检测EC患者化疗敏感性血清蛋白质谱。结果:两组差异斑点共有68个,以耐药组为参照,敏感组患者血清蛋白下调的斑点有42个,上调的斑点有26个。从这68个差异斑点中筛选出8个斑点进行质谱鉴定,通过数据库检索分析和鉴定最终确定上述斑点所对应的蛋白质名称分别为Kininogen-1,Alpha-2-HS-glycoprotein,Fibrinogen beta chain,Clusterin,Retinol-binding protein 4,Beta-2-glycoprotein 1,Ig kappa chain C region,Complement C4-A。结论:基于铂类化疗的EC敏感患者和耐药患者间存在差异表达蛋白。
Objective: To determine the chemosensitivity serum protein profile of esophageal cancer (EC) patients by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and to guide the selection of chemotherapy regimens for clinical EC patients. METHODS: Forty patients with recurrent platinum-based chemotherapy after EC from January 2013 to June 2014 were collected. The patients were divided into sensitive group and drug-resistant group according to the efficacy of chemotherapy. The two-dimensional protein two-dimensional gel electrophoresis patterns were analyzed and matched with Image Master 2D platinum 5.0 software. Two sets of differential spots were screened, and the MALDI-TOF-MS technique was used to detect the chemosensitivity serum protein profile of EC patients. RESULTS: There were 68 differential spots in the two groups, and the resistance group was used as a reference. In the sensitive group, there were 42 spots with down-regulated serum proteins and 26 spots with up-regulated spots. Eight spots were screened from these 68 spots for mass spectrometry identification. The protein names corresponding to the above spots were identified by database search analysis and identification as Kininogen-1, Alpha-2-HS-glycoprotein, Fibrinogen beta chain, Clusterin. Retinol-binding protein 4, Beta-2-glycoprotein 1, Ig kappa chain C region, Complement C4-A. CONCLUSIONS: Differentially expressed proteins are present between EC-sensitive patients and drug-resistant patients based on platinum-based chemotherapy.